Want to see HK:0719 full AI Analyst Report?
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Ratios
Shandong Xinhua Pharmaceutical Company Limited Class H Ratios
HK:0719's free cash flow for Q3 2026 was $-10.30M. For the 2026 fiscal year, HK:0719's free cash flow was decreased by $-31.23M and operating cash flow was $20.93M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.43 | 1.33 | 1.33 | 1.09 | 1.10 |
| Quick Ratio | 0.97 | 0.88 | 0.81 | 0.71 | 0.69 |
| Cash Ratio | 0.50 | 0.45 | 0.37 | 0.37 | 0.30 |
| Solvency Ratio | 0.24 | 0.27 | 0.29 | 0.23 | 0.21 |
| Operating Cash Flow Ratio | 0.19 | 0.13 | 0.11 | 0.24 | 0.10 |
| Short-Term Operating Cash Flow Coverage | 0.40 | 0.63 | 0.93 | 6.42 | 0.96 |
| Net Current Asset Value | $ 303.63M | $ -75.26M | $ -196.08M | $ -458.27M | $ -926.93M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.15 | 0.13 | 0.17 | 0.14 |
| Debt-to-Equity Ratio | 0.25 | 0.27 | 0.24 | 0.34 | 0.30 |
| Debt-to-Capital Ratio | 0.20 | 0.21 | 0.19 | 0.25 | 0.23 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.13 | 0.15 | 0.12 | 0.09 |
| Financial Leverage Ratio | 1.76 | 1.81 | 1.82 | 2.00 | 2.11 |
| Debt Service Coverage Ratio | 0.68 | 1.72 | 3.27 | 5.76 | 2.63 |
| Interest Coverage Ratio | 8.40 | 13.45 | 12.99 | 9.59 | 8.01 |
| Debt to Market Cap | 0.50 | 0.36 | 0.30 | 0.14 | 0.26 |
| Interest Debt Per Share | 1.97 | 2.04 | 1.63 | 2.16 | 1.76 |
| Net Debt to EBITDA | -0.09 | 0.10 | 0.15 | 0.22 | 0.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 18.78% | 24.11% | 28.66% | 27.15% | 27.04% |
| EBIT Margin | 4.58% | 6.77% | 7.08% | 6.95% | 7.23% |
| EBITDA Margin | 11.30% | 13.16% | 13.46% | 13.47% | 13.85% |
| Operating Profit Margin | 4.16% | 6.31% | 6.60% | 6.35% | 6.49% |
| Pretax Profit Margin | 4.10% | 6.30% | 6.58% | 6.29% | 6.42% |
| Net Profit Margin | 3.31% | 5.55% | 6.13% | 5.48% | 5.31% |
| Continuous Operations Profit Margin | 3.50% | 5.75% | 6.25% | 5.68% | 5.52% |
| Net Income Per EBT | 80.77% | 88.08% | 93.21% | 87.13% | 82.74% |
| EBT Per EBIT | 98.61% | 99.87% | 99.65% | 98.97% | 98.98% |
| Return on Assets (ROA) | 3.15% | 5.21% | 5.99% | 4.97% | 4.75% |
| Return on Equity (ROE) | 5.56% | 9.42% | 10.90% | 9.96% | 10.05% |
| Return on Capital Employed (ROCE) | 5.71% | 8.59% | 9.22% | 9.34% | 8.81% |
| Return on Invested Capital (ROIC) | 4.03% | 7.16% | 8.35% | 8.24% | 7.17% |
| Return on Tangible Assets | 3.37% | 5.56% | 6.37% | 5.28% | 5.08% |
| Earnings Yield | 7.10% | 12.62% | 13.75% | 8.61% | 14.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.19 | 7.50 | 8.53 | 7.73 | 7.54 |
| Payables Turnover | 9.05 | 5.54 | 4.91 | 5.01 | 4.49 |
| Inventory Turnover | 5.39 | 5.05 | 4.40 | 4.51 | 4.66 |
| Fixed Asset Turnover | 2.11 | 1.97 | 1.99 | 1.88 | 1.74 |
| Asset Turnover | 0.95 | 0.94 | 0.98 | 0.91 | 0.89 |
| Working Capital Turnover Ratio | 8.13 | 9.62 | 14.38 | 27.26 | 23.52 |
| Cash Conversion Cycle | 78.12 | 55.17 | 51.30 | 55.36 | 45.47 |
| Days of Sales Outstanding | 50.76 | 48.68 | 42.77 | 47.22 | 48.43 |
| Days of Inventory Outstanding | 67.69 | 72.31 | 82.92 | 80.94 | 78.36 |
| Days of Payables Outstanding | 40.33 | 65.83 | 74.39 | 72.80 | 81.32 |
| Operating Cycle | 118.45 | 120.99 | 125.69 | 128.16 | 126.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.77 | 0.54 | 0.38 | 1.14 | 0.42 |
| Free Cash Flow Per Share | 0.61 | 0.23 | -0.09 | 0.77 | 0.02 |
| Dividend Paid and CapEx Coverage Ratio | 1.64 | 0.84 | 0.53 | 1.86 | 0.65 |
| Capital Expenditure Coverage Ratio | 4.62 | 1.73 | 0.82 | 3.10 | 1.04 |
| Operating Cash Flow Coverage Ratio | 0.41 | 0.27 | 0.24 | 0.55 | 0.25 |
| Operating Cash Flow to Sales Ratio | 0.06 | 0.04 | 0.03 | 0.10 | 0.04 |
| Free Cash Flow Yield | 10.24% | 4.17% | -1.66% | 10.76% | 0.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 14.09 | 7.91 | 7.27 | 11.61 | 6.76 |
| Price-to-Sales (P/S) Ratio | 0.47 | 0.44 | 0.45 | 0.64 | 0.36 |
| Price-to-Book (P/B) Ratio | 0.78 | 0.75 | 0.79 | 1.16 | 0.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.76 | 23.99 | -60.34 | 9.29 | 238.33 |
| Price-to-Operating Cash Flow Ratio | 7.65 | 10.13 | 13.61 | 6.29 | 9.10 |
| Price-to-Earnings Growth (PEG) Ratio | -0.36 | -1.90 | 0.45 | 1.08 | 0.88 |
| Enterprise Value Multiple | 4.04 | 3.44 | 3.46 | 4.94 | 2.92 |
| Enterprise Value | 4.00B | 3.83B | 3.78B | 5.00B | 2.66B |
| EV to EBITDA | 4.04 | 3.44 | 3.46 | 4.94 | 2.92 |
| EV to Sales | 0.46 | 0.45 | 0.47 | 0.67 | 0.40 |
| EV to Free Cash Flow | 9.56 | 24.69 | -63.12 | 9.73 | 268.57 |
| EV to Operating Cash Flow | 7.49 | 10.42 | 14.24 | 6.59 | 10.25 |
| Tangible Book Value Per Share | 7.06 | 6.82 | 6.21 | 5.84 | 5.12 |
| Shareholders’ Equity Per Share | 7.56 | 7.31 | 6.60 | 6.22 | 5.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.09 | 0.05 | 0.10 | 0.14 |
| Revenue Per Share | 12.70 | 12.41 | 11.75 | 11.31 | 10.54 |
| Net Income Per Share | 0.42 | 0.69 | 0.72 | 0.62 | 0.56 |
| Tax Burden | 0.81 | 0.88 | 0.93 | 0.87 | 0.83 |
| Interest Burden | 0.89 | 0.93 | 0.93 | 0.90 | 0.89 |
| Research & Development to Revenue | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| SG&A to Revenue | 0.04 | 0.07 | 0.06 | 0.02 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Income Quality | 1.74 | 0.76 | 0.53 | 1.78 | 0.72 |
Currency in CNY